Despite the challenges traditionally associated with copper-67 production a number of highly successful human clinical trials have been performed with antibodies linked to copper-67 payload, demonstrating high response rates, higher tumor uptake and doses, and longer residence time in tumor than alternate radioisotopes. The targeted diseases include Non-Hodgkin Lymphoma (NHL), colon and bladder cancer.
New clinical trials are now underway.
Click on the links below to access published articles, or contact us for further information:
Iotron Medical, a spin-out business of Iotron Industries - providing innovative solutions using electron beam technology for more than 25 years
Canadian Isotope Innovations, operating the most capable radioisotope electron accelerator in North America today
If you have any queries or wish to contact us:
For partnering opportunities:
To buy radioisotope: